EQS-News: DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUM(TM) -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUM(TM)-mRNA CANCER VACCINE PROGRAM BEGINS

CSE: DTC       FSE: DTC       USOTC: DTCFF       PRESS RELEASE 

DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUM^TM -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUM^TM-mRNA CANCER VACCINE PROGRAM BEGINS

Vancouver, BC, Canada, April 11^th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to Accum^TM. The potency of this modified product will now be compared to "naked" mRNA administered as vaccines in immunocompetent mice. 

The field of mRNA vaccination holds great promises over the use of other vaccination modalities. mRNA delivered to target cells makes them prone to harsh intracellular conditions such as the exhaustive acidity and enzymatic reactions found within endosomal lumens. As such, captured mRNA molecules may be destroyed before even reaching the cytoplasm where they are normally translated into proteins or long polypeptide chains. When tested in mice, administration of a "naked" mRNA molecule encoding for the ovalbumin protein triggered a weak to moderate antibody titers. 

“Despite representing a promising technology, mRNA vaccines have not reached their full potential yet. By conjugating mRNA to Accum^TM, we anticipate the immunogenicity of the vaccine to be enhanced resulting therefore in a powerful immune response" says Dr. Rafei, the VP research and development of Defence Therapeutics. 

Defence has now completed its Accum^TM-mRNA vaccine engineering and synthesis. The final product is stable, and an SOP has been finalized to be able to apply the same method to any chosen mRNA molecule.

“The Defence Accum^TM-mRNA vaccine program is on schedule. With this engineering steps completed, we are now initiating in vivo studies to compare the immunogenicity of the vaccine. The potency of the Accum^TM-mRNA vaccine will be tested in animals on cancer solid T-cell lymphoma first, then subsequently on additional cancer solid tumors”, says Mr. Plouffe, CEO of Defence Therapeutics.

Defence plans to develop its own Accum^TM-linked mRNA vaccines for different cancer indications. In parallel, the company is actively working on establishing partnerships with companies currently testing/developing mRNA vaccines for both immune-oncology and infectious disease indications.

The mRNA therapeutics market size is projected to surpass around USD 128.14 billion by 2030 and growing at a registered CAGR of 13.03% from 2022 to 2030 according to Precedence Research.

https://www.precedenceresearch.com/mrna-therapeutics-market#:~:text=The%20mRNA%20therapeutics%20market%20size,forecast%20period%202022%20to%202030

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

[email protected]

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.